DARC for AMD
Age-related Macular Degeneration
Exploratory Biomarker in Clinical StudiesActive
Key Facts
Indication
Age-related Macular Degeneration
Phase
Exploratory Biomarker in Clinical Studies
Status
Active
Company
About Novai
Novai is a private, clinical-stage UK MedTech company developing a novel diagnostic and biomarker platform called DARC. The technology detects apoptosing retinal cells in vivo, providing an early, objective measure of disease activity for conditions like glaucoma and age-related macular degeneration (AMD). Founded and led by renowned clinician-scientist Prof. Francesca Cordeiro, the company is positioning DARC as a tool to empower earlier patient intervention, guide clinician treatment decisions, and de-risk drug development for pharmaceutical partners. Novai appears to be in a pre-revenue, late-stage development phase, advancing its technology through clinical studies.
View full company profileTherapeutic Areas
Other Age-related Macular Degeneration Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Program (AMD) | Cloudbreak Pharmaceutical | Pre-clinical / Clinical |
| hOTX2 | BrainEver | Discovery |
| Undisclosed AMD Program | Mobius Scientific | Preclinical |
| iPSC-derived RPE cells | Healios | Preclinical/Research |